EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring

Tim van den Heuvel iD, Ralf Kolassa, Winfried Keuthage, Jens Kroeger, Roseline Ré, Simona de Portu, Linda Vorrink, John Shin, Javier Castañeda, Robert Vigersky iD, Ohad Cohen

Journal of Diabetes Science and Technology · 2024

DOI: 10.1177/19322968231161320 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Science and Technology, 2024. Verfasst von Tim van den Heuvel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medtronic International Trading Sàrl, Tolochenaz, Switzerland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Blood Glucose Self-Monitoring, Blood Glucose, Insulin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medtronic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This analysis reports the findings from a predefined exploratory cohort (cohort B) from the ADAPT (ADvanced Hybrid Closed Loop Study in Adult Population with Type 1 Diabetes) study. Adults with type 1 diabetes (T1D) with suboptimal glucose control were randomly allocated to an advanced hybrid closed-loop (AHCL) system or multiple daily injections of insulin (MDI) plus real-time continuous glucose monitoring (RT-CGM).

Methods

In this prospective, multicenter, exploratory, open-label, randomized controlled trial, 13 participants using MDI + RT-CGM and with HbA1c ≥8.0% were randomized to switch to AHCL (n = 8) or continue with MDI + RT-CGM (n = 5) for six months. Prespecified endpoints included the between-group difference in mean change from baseline in HbA1c, CGM-derived measures of glycemic control, and safety.

Results

The mean HbA1c level decreased by 1.70 percentage points in the AHCL group versus a 0.60 percentage point decrease in the MDI + RT-CGM group, with a model-based treatment effect of −1.08 percentage points (95% confidence interval [CI] = −2.17 to 0.00 percentage points; P = .0508) in favor of AHCL. The percentage of time spent with sensor glucose levels between 70 and 180 mg/dL in the study phase was 73.6% in the AHCL group and 46.4% in the MDI + RT-CGM group; model-based between-group difference of 28.8 percentage points (95% CI = 12.3 to 45.3 percentage points; P = .0035). No diabetic ketoacidosis or severe hypoglycemia occurred in either group.

Conclusions

In people with T1D with HbA1c ≥8.0%, the use of AHCL resulted in improved glycemic control relative to MDI + RT-CGM. The scale of improvement suggests that AHCL should be considered as an option for people not achieving good glycemic control on MDI + RT-CGM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Blood Glucose Self-MonitoringBlood GlucoseInsulinHypoglycemic AgentsInsulin Infusion SystemsGlycated HemoglobinHumansAdultMaleFemaleMiddle AgedProspective StudiesGlycemic ControlContinuous Glucose Monitoring

Stichwörter der Autor:innen

HbA1cautomated insulin deliveryclosed-loop systemdiabeteshyperglycemiahypoglycemiatime in range

Substanzen

Blood GlucoseInsulinHypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
  • Diabetologische Schwerpunktpraxis, Bergheim, Germany.
  • Medical Center am Clemenshospital, Münster, Germany.
  • Zentrum für Diabetologie Bergedorf, Hamburg, Germany.
  • Medtronic, Northridge, CA, USA.

ORCID-Profile: Tim van den Heuvel, Robert Vigersky

Förderung

  • Medtronic

Zitieren

APA

van den Heuvel, T., Kolassa, R., Keuthage, W., Kroeger, J., Ré, R., de Portu, S., Vorrink, L., Shin, J., Castañeda, J., Vigersky, R., & Cohen, O. (2024). Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968231161320

Vancouver

van den Heuvel T, Kolassa R, Keuthage W, Kroeger J, Ré R, de Portu S, et al. Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring. Journal of Diabetes Science and Technology. 2024. doi:10.1177/19322968231161320

BibTeX
@article{vandenHeuvel2024,
  author = {van den Heuvel, Tim and Kolassa, Ralf and Keuthage, Winfried and Kroeger, Jens and Ré, Roseline and de Portu, Simona and Vorrink, Linda and Shin, John and Castañeda, Javier and Vigersky, Robert and Cohen, Ohad},
  title = {Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring},
  journal = {Journal of Diabetes Science and Technology},
  year = {2024},
  doi = {10.1177/19322968231161320}
}
Kostenlos starten →